Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
Won YW, Kang JH, Kwon JH, Koo DH, Kang JH, Maeng CH, Ahn HK, Oh SY, Lee DW, Sohn J, Oh SY, Lee KH, Koh SJ, Lee KS, Kim CK, Kim JY, Ji JH, Kim SB, Ha JY, Kim HY. Won YW, et al. Among authors: lee ks, lee kh, lee dw. Cancer Res Treat. 2023 Oct;55(4):1096-1103. doi: 10.4143/crt.2022.1565. Epub 2023 Apr 7. Cancer Res Treat. 2023. PMID: 37054719 Free PMC article.
Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea.
Ryoo HG, Suh M, Kang KW, Lee DW, Han SW, Cheon GJ. Ryoo HG, et al. Among authors: lee dw. Cancer Res Treat. 2023 Jan;55(1):334-343. doi: 10.4143/crt.2021.1022. Epub 2022 Apr 22. Cancer Res Treat. 2023. PMID: 35468268 Free PMC article. Clinical Trial.
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
Ahn HK, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, Kim JH, Lee KS, Sohn JH, Choi YL, Im SA, Jung KH, Park YH. Ahn HK, et al. Among authors: lee ks, lee kh, lee dw. JAMA Oncol. 2022 Sep 1;8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310. JAMA Oncol. 2022. PMID: 35797012 Free PMC article. Clinical Trial.
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03).
Lee DW, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Lee MH, Kim JH, Lee KE, Kim HJ, Kim SY, Park YH, Ock CY, Lee KH, Han SW, Kim SB, Im YH, Chung HC, Oh DY, Im SA. Lee DW, et al. Among authors: lee ks, lee mh, lee ke, lee kh. Cancer Res Treat. 2023 Apr;55(2):523-530. doi: 10.4143/crt.2022.1360. Epub 2022 Nov 8. Cancer Res Treat. 2023. PMID: 36397238 Free PMC article. Clinical Trial.
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial.
Lee DW, Jung KH, Lee KH, Park YH, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh SJ, Kim JH, Kim HJ, Lee KE, Kim HJ, Yang YW, Park KH, Lee J, Won HS, Kim TY, Im SA. Lee DW, et al. Among authors: lee ks, lee ke, lee j, lee kh. Eur J Cancer. 2024 Jan;197:113456. doi: 10.1016/j.ejca.2023.113456. Epub 2023 Nov 20. Eur J Cancer. 2024. PMID: 38104354 Clinical Trial.
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).
Baek SK, Jeong JH, Jung K, Ahn HK, Kim MH, Sohn J, Park IH, Ahn JS, Lee DW, Im SA, Sim SH, Lee KS, Hyun Kim J, Shim HJ, Chae Y, Koh SJ, Lee H, Lee J, Byun JH, Seol Y, Lee EM, Jee HJ, An H, Park EB, Suh YJ, Lee KE, Park YH; Korean Cancer Study Group (KCSG). Baek SK, et al. Among authors: lee ks, lee h, lee em, lee j, lee ke, lee dw. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231225029. doi: 10.1177/17588359231225029. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38288157 Free PMC article.
2,297 results